HCTZ-Induced Hyperuricemia
Yes, hydrochlorothiazide (HCTZ) definitively causes hyperuricemia and can precipitate acute gout attacks, and when feasible, you should switch HCTZ to an alternative antihypertensive agent in patients with gout or problematic hyperuricemia. 1
Mechanism and Clinical Significance
HCTZ raises serum uric acid through decreased renal uric acid secretion and increased reabsorption 2. The FDA label explicitly warns that "hyperuricemia or acute gout may be precipitated in certain patients receiving thiazide diuretics" 3. This is a well-established, dose-dependent adverse effect that occurs consistently across patient populations.
Research demonstrates substantial uric acid elevations—up to 1.8 mg/dL in individuals homozygous for certain risk alleles 4. Even at lower doses (6.25 mg), HCTZ causes measurable increases in uric acid, though the incidence of clinical hyperuricemia is reduced compared to standard 25 mg doses 5.
Management Algorithm
For Patients with Established Gout
Switch HCTZ to an alternative antihypertensive when feasible 1. The 2020 ACR Gout Guidelines provide a conditional recommendation for this approach, emphasizing that medication changes should only occur when the benefits of uric acid reduction exceed the risks of changing blood pressure therapy.
Preferred alternative: Losartan 1, 6. The ACR conditionally recommends choosing losartan preferentially as an antihypertensive in gout patients, as it has modest urate-lowering effects. The EULAR 2016 guidelines similarly recommend losartan or calcium channel blockers as alternatives 6.
For Patients Developing Hyperuricemia on HCTZ
The decision depends on several factors:
- If the patient has symptomatic hyperuricemia or gout attacks: Switch to an alternative antihypertensive
- If asymptomatic hyperuricemia without gout history: The evidence is more nuanced. A 2023 trial showed no significant benefit of HCTZ for kidney stone prevention, but notably documented increased rates of gout, hypokalemia, and new-onset diabetes as adverse effects 7
Important Caveats
Do not stop HCTZ if it's the only effective agent controlling blood pressure. The guidelines explicitly state that switching should only occur "when feasible" and when benefits exceed risks 1. Uncontrolled hypertension carries greater morbidity and mortality risk than asymptomatic hyperuricemia.
Blood pressure control level matters: Interesting data suggests that achieving SBP 130-139 mmHg (rather than <130 or ≥140 mmHg) is associated with smaller uric acid increases and lower rates of incident hyperuricemia when using HCTZ combinations 8. This suggests a "sweet spot" for blood pressure targets that minimizes uric acid elevation.
Risk Factors for HCTZ-Induced Hyperuricemia
Machine learning analysis identified key clinical determinants 9:
- Uncontrolled diabetes
- Lower baseline eGFR
- Absence of SGLT2 inhibitors
- Absence of statin treatment
- Older age
- Use of indapamide (thiazide-like diuretic)
Protective factors: Estrogen-progestin therapy in postmenopausal women can reverse HCTZ-induced hyperuricemia by improving renal plasma flow and uric acid excretion 10.
Monitoring
Periodic serum electrolyte and uric acid monitoring is essential 3. Watch for:
- Serum uric acid elevations
- Hypokalemia (which commonly co-occurs)
- Signs of acute gout (joint pain, swelling, erythema)
When HCTZ Cannot Be Discontinued
If HCTZ must be continued and the patient develops gout or symptomatic hyperuricemia:
- Initiate urate-lowering therapy (allopurinol or febuxostat) with a treat-to-target approach aiming for serum uric acid <6 mg/dL 1
- Consider adding spironolactone, which may help mitigate some metabolic effects while maintaining blood pressure control 11
The key principle: Switching HCTZ to losartan or calcium channel blockers is preferred when feasible in gout patients, but maintaining blood pressure control always takes precedence over managing asymptomatic hyperuricemia.